TABLE 1.

Activity of aztreonam–β-lactamase inhibitor combinations and comparator agents against tested clinical Stenotrophomonas maltophilia isolates^a

Agent(s)	MIC (mg/liter)			% susceptible
	50%	90%	Range
Aztreonam	≥256	≥256	8 to ≥256	2.1
Aztreonam-avibactamb	4	4	0.5 to 16	97.9
Aztreonam-clavulanatec	8	≥256	1 to ≥256	61.7
Aztreonam-clavulanated	4	128	1 to ≥256	61.7
Aztreonam-relebactame	8	16	1 to 128	72.3
Aztreonam-vaborbactamf	32	128	2 to ≥256	17.0
Aztreonam-vaborbactamg	64	≥256	2 to ≥256	6.4
Amoxicillin-clavulanate	≥256	≥256	16 to ≥256
Ceftazidime-avibactamh	64	128	0.125 to ≥256	25.5
Imipenem-relebactam	≥64	≥64	0.5 to ≥64
Levofloxacin	8	≥32	0.25 to ≥32	38.3
Meropenem-vaborbactam	≥64	≥64	0.25 to ≥64
Trimethoprim-sulfamethoxazolei	8	≥16	0.03 to ≥16	44.7

^an = 47 isolates. Susceptibility interpretations of aztreonam-based regimens were based on CLSI aztreonam interpretive criteria against P. aeruginosa (34).

^bAvibactam tested at 4 mg/liter.

^cClavulanate tested at 2 mg/liter.

^dClavulanate tested at 4 mg/liter.

^eRelebactam tested at 4 mg/liter.

^fVaborbactam tested at 8 mg/liter.

^gVaborbactam tested at 4 mg/liter.

^hSusceptibility interpretation based on CLSI ceftazidime interpretative criteria against S. maltophilia (34).

ⁱReflects the MIC of the trimethoprim component only.